ALSO NOTED: Shareholders upset at Mylan meeting move; Ranbaxy launches biogeneric for osteoporosis;

> Mylan Laboratories has moved its annual meeting from Pittsburgh to New Jersey, riling longtime shareholders in Pennsylvania. Report

> Mumbai-based Ranbaxy Laboratories launched a biogeneric treatment for osteoporosis in India, the first copycat recombinant drug in the world, the company said. Report

> GlaxoSmithKline strengthened warnings on its anti-flu med Relenza, citing psychiatric effects such as hallucinations and delirium in some patients using the drug. Report | Letter

> India's Dr. Reddy's Laboratories setting up a beachhead in Italy with the acquisition of Jet Generic, a maker of copycat drugs. Report

> The Chinese market for gastric cancer drugs will nearly triple between 2007 and 2012, fueled by increased access to health insurance and greater patient spending power, a new report shows. Release

> Japanese scientists have found a way to deliver a payload of artificial molecules designed to prevent cells from secreting collagen, possibly pointing to a new approach to treating cirrhosis. Report

> The recent revelation in the New York Times that a tobacco company had quietly--some say secretly--funded a research program on lung cancer prompted the Boston Globe to go out in search of tobacco money behind local research groups. It didn't have to go very far. Report

> A professor at the California Institute of Technology is walking away with the $1 million Gotham Prize for an original approach to killing cancer cells. Report

> Turmoil on the Street has created a bleak financial landscape for emerging biotech companies. Report

> Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more effective than standard chemotherapy. Report

> Shares of Opko and Alnylam have slid since a new study published in late March concluded that experimental drugs developed with the hot new science of RNA interference may work by activating the human immune system rather than by silencing select genes. Report

And Finally... Coffee may cut the risk of dementia by blocking the damage cholesterol can inflict on the body, research suggests. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.